Abdominal Aortic Aneurysm Market

Market Overview: 

The 7 major abdominal aortic aneurysm markets reached a value of US$ 1,692.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3,235.2 Million by 2034, exhibiting a growth rate (CAGR) of 6.07% during 2024-2034.

The abdominal aortic aneurysm market has been comprehensively analyzed in IMARC's new report titled "Abdominal Aortic Aneurysm Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". An abdominal aortic aneurysm (AAA) refers to a condition where a section of the aorta becomes enlarged and weakened, causing it to bulge outward. It is most commonly found in the lower part of the aorta in the abdomen and can grow over time, increasing the risk of rupture and life-threatening bleeding. In most cases, abdominal aortic aneurysms do not cause any symptoms, and they are often discovered incidentally during routine medical exams or imaging tests done for other reasons. However, some people with AAAs may experience various symptoms, such as constant pain in the abdomen, a pulsating feeling near the navel, back pain, leg pain, etc. These indications may be more common if the aneurysm is growing rapidly or pressing on nearby organs or nerves. The disorder can be diagnosed through a physical examination, several imaging tests, and blood tests. During the physical exam, a pulsating mass in the abdomen can indicate the presence of an AAA. Various imaging tests, including ultrasound, CT scan, MRI, etc., can confirm the diagnosis and provide information about the size, location, and shape of the aneurysm. Additionally, blood tests can also help diagnose AAA by measuring levels of specific proteins associated with the condition.

The increasing prevalence of atherosclerosis and infectious aortitis is primarily driving the abdominal aortic aneurysm market. Furthermore, the inflating cases of several associated risk factors, such as genetic disorders of connective tissue and congenital syndromes, are also augmenting the market growth. In addition to this, the escalating utilization of effective drugs, including beta-blockers, statins, angiotensin-converting enzyme (ACE) inhibitors, etc., for managing AAA-related complications, such as hypertension and atherosclerosis, is creating a positive outlook for the market. Moreover, the emerging popularity of endovascular aneurysm repair (EVAR), a minimally invasive approach, on account of its numerous advantages over open surgery, including shorter hospital stays, faster recovery times, and reduced risk of complications, is also bolstering the market. Apart from this, several key players are making extensive investments in developing drugs that prevent or delay the progression of AAA, which could potentially lower the need for surgical interventions. This, in turn, is acting as another significant growth-inducing factor. Additionally, the introduction of new endovascular devices, such as branched and fenestrated stent grafts, to treat complex AAA cases is further propelling the market growth. These devices can be custom-made to fit patient's specific anatomy and can reduce the requirement for open surgery. Besides this, the widespread adoption of hybrid procedures, which combine surgery and endovascular repair, and offer a tailored approach to AAA treatment for patients with complex anatomies or high-risk factors, is expected to drive the abdominal aortic aneurysm market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the abdominal aortic aneurysm market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for abdominal aortic aneurysm and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the abdominal aortic aneurysm market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the abdominal aortic aneurysm market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the abdominal aortic aneurysm market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current abdominal aortic aneurysm marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the abdominal aortic aneurysm market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the abdominal aortic aneurysm market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the abdominal aortic aneurysm market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of abdominal aortic aneurysm across the seven major markets?
• What is the number of prevalent cases (2018-2034) of abdominal aortic aneurysm by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of abdominal aortic aneurysm by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with abdominal aortic aneurysm across the seven major markets?
• What is the size of the abdominal aortic aneurysm patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of abdominal aortic aneurysm?
• What will be the growth rate of patients across the seven major markets?
   

Abdominal Aortic Aneurysm: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for abdominal aortic aneurysm drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the abdominal aortic aneurysm market?
• What are the key regulatory events related to the abdominal aortic aneurysm market?
• What is the structure of clinical trial landscape by status related to the abdominal aortic aneurysm market?
• What is the structure of clinical trial landscape by phase related to the abdominal aortic aneurysm market?
• What is the structure of clinical trial landscape by route of administration related to the abdominal aortic aneurysm market?